Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with RFA or SIRT in inoperable hepatocellular carcinoma with Primovist MRI treatment assignment study
NL-OMON41292Phase 2Active, not recruiting
- Sponsor
- Otto von Guericke University Magdeburg
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sorafenib in hepatocellular carcinoma (HCC) and liver cancer (4 arms), sponsored by Otto von Guericke University Magdeburg. Primary endpoints: Time to recurrence, Overall survival and 1 more. Started Jun 2011; status: active, not recruiting.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on NL-OMON41292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41292.